Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
5(56%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
9
100%

Phase Distribution

9

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
9(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

9

all time

Status Distribution
Active(8)
Completed(1)

Detailed Status

Recruiting5
Not yet recruiting3
Completed1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
5
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 19 (100.0%)

Trials by Status

not_yet_recruiting333%
recruiting556%
completed111%

Recent Activity

5 active trials
Showing 5 of 9
not_yet_recruitingphase_1

Research on YTS109 Cell in Patients With Recurrent/Refractory Autoimmune Hemolytic Anemia

NCT07453836
recruitingphase_1

An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

NCT07236762
completedphase_1

A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia

NCT07075484
recruitingphase_1

Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases

NCT07236801
recruitingphase_1

A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

NCT07104721
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07453836Phase 1

Research on YTS109 Cell in Patients With Recurrent/Refractory Autoimmune Hemolytic Anemia

Not Yet Recruiting
NCT07236762Phase 1

An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Recruiting
NCT07075484Phase 1

A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia

Completed
NCT07236801Phase 1

Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases

Recruiting
NCT07104721Phase 1

A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Recruiting
NCT07123519Phase 1

A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

Recruiting
NCT07439029Phase 1

YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases

Not Yet Recruiting
NCT07287930Phase 1

A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia

Not Yet Recruiting
NCT06978647Phase 1

A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases

Recruiting

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9